After 3 Years of Pressure, FDA Declares NMN Legal in Dietary Supplements

FDA Confirms NMN’s Legal Status in Supplements

On September 29, 2025, the U.S. Food and Drug Administration (FDA) officially reversed its prior stance and declared that β-Nicotinamide Mononucleotide (NMN) is lawful for use in dietary supplements.

This landmark decision followed nearly three years of petitions, lawsuits, and persistent advocacy from the Natural Products Association (NPA), which argued that FDA’s earlier attempt to block NMN was an overreach of its authority.

The FDA had previously attempted to exclude NMN by invoking the “drug preclusion clause” of the Dietary Supplement Health and Education Act (DSHEA), claiming that NMN had first been investigated as a pharmaceutical drug. The NPA countered with evidence showing that NMN was marketed as a supplement in the U.S. as early as 2017, making it legally eligible as a dietary supplement.

Why This Decision Matters

The FDA’s confirmation has immediate consequences for consumers, brands, and e-commerce platforms:

• Restored Consumer Access → NMN products, once restricted or removed from platforms like Amazon, can now be lawfully sold again.
• Regulatory Clarity → The decision sets an important precedent for other natural compounds that face similar drug preclusion challenges.
• Scientific Progress → Researchers and biohackers alike can continue using NMN to explore its benefits in energy metabolism, DNA repair, and healthy aging.

As Daniel Fabricant, Ph.D., President and CEO of the NPA, stated:

“FDA’s decision today confirms NMN is lawful in supplements, and we now call on e-commerce platforms to immediately restore NMN products to the market.”

A Pattern of FDA Reversals

This is not the first time the FDA has changed course under pressure. In 2022, the agency attempted to remove N-acetyl-L-cysteine (NAC) from the supplement market. After NPA’s legal action, the FDA ultimately allowed NAC to remain available under a policy of enforcement discretion.

The NMN case further solidifies the role of the NPA as a leading advocate for supplement access, especially as it approaches its 90th anniversary in 2026.

What It Means for Longevity and Biohackers

For the longevity community, the FDA’s confirmation is more than a legal technicality—it’s a validation of NMN’s rightful place in nutritional science.

• NMN supports NAD+ levels, the cellular “fuel” essential for energy, DNA repair, and resilience against aging.
• Clinical studies suggest NMN supplementation may improve stamina, metabolic health, cognitive clarity, and recovery.
• With FDA’s recognition, consumers can feel more confident purchasing NMN products—provided they come from brands that prioritize purity, stability, and third-party testing.

Genevity+ Perspective

We welcome this decision because it restores transparency and consumer trust in longevity science. But it also raises a critical point:

Not all NMN is created equal.

• NMN degrades quickly at room temperature.
• Products stored in warm warehouses may arrive with little to no active NMN remaining.
• For true efficacy, NMN must be manufactured in small, fresh batches, tested for purity, and stored in cold-chain conditions until it reaches your hands.

That’s why every batch of Genevity+ NMN Lipo is:
✅ Third-party tested for purity and potency
✅ Produced in small, frequent batches for freshness
✅ Cold-stored below 7°C in our U.S. 3PL warehouse

Because science only works if your supplement delivers what’s on the label.

Final Thoughts

The FDA’s confirmation of NMN as a lawful supplement is a historic win for consumers, scientists, and the longevity movement. It ensures continued access to one of the most researched and promising molecules for healthy aging.

As momentum builds in aging research, one thing is clear: we now have the regulatory green light to keep pushing the frontier of cellular health forward.